Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)

Philip Raskin; Alok Mohan

doi:10.1517/14656566.2010.497142

Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)

Philip Raskin, Alok Mohan

Research output: Contribution to journal › Comment/debate › peer-review

8 Scopus citations

Abstract

The safety and efficacy of exenatide once weekly is evaluated over 52 weeks in the DURATION-1 trial in patients with type 2 diabetes. This long-acting glucagon-like peptide 1 receptor agonist given as a once weekly subcutaneous injection was found to produce better glycemic control as compared to twice daily exenatide and had a good safety profile over the trial period. Its use can help to reduce the complexity of drug regimen in patients with type 2 diabetes while maintaining a good safety and efficacy profile.

Original language	English (US)
Pages (from-to)	2269-2271
Number of pages	3
Journal	Expert Opinion on Pharmacotherapy
Volume	11
Issue number	13
DOIs	https://doi.org/10.1517/14656566.2010.497142
State	Published - Sep 1 2010

Keywords

DURATION-1 trial
Exenatide
GLP-1 receptor agonist
Type 2 diabetes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/14656566.2010.497142

Cite this

@article{0bbe0274abfd4a25b75f9c2188f18bd6,

title = "Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)",

abstract = "The safety and efficacy of exenatide once weekly is evaluated over 52 weeks in the DURATION-1 trial in patients with type 2 diabetes. This long-acting glucagon-like peptide 1 receptor agonist given as a once weekly subcutaneous injection was found to produce better glycemic control as compared to twice daily exenatide and had a good safety profile over the trial period. Its use can help to reduce the complexity of drug regimen in patients with type 2 diabetes while maintaining a good safety and efficacy profile.",

keywords = "DURATION-1 trial, Exenatide, GLP-1 receptor agonist, Type 2 diabetes",

author = "Philip Raskin and Alok Mohan",

year = "2010",

month = sep,

day = "1",

doi = "10.1517/14656566.2010.497142",

language = "English (US)",

volume = "11",

pages = "2269--2271",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Informa Healthcare",

number = "13",

}

TY - JOUR

T1 - Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)

AU - Raskin, Philip

AU - Mohan, Alok

PY - 2010/9/1

Y1 - 2010/9/1

N2 - The safety and efficacy of exenatide once weekly is evaluated over 52 weeks in the DURATION-1 trial in patients with type 2 diabetes. This long-acting glucagon-like peptide 1 receptor agonist given as a once weekly subcutaneous injection was found to produce better glycemic control as compared to twice daily exenatide and had a good safety profile over the trial period. Its use can help to reduce the complexity of drug regimen in patients with type 2 diabetes while maintaining a good safety and efficacy profile.

AB - The safety and efficacy of exenatide once weekly is evaluated over 52 weeks in the DURATION-1 trial in patients with type 2 diabetes. This long-acting glucagon-like peptide 1 receptor agonist given as a once weekly subcutaneous injection was found to produce better glycemic control as compared to twice daily exenatide and had a good safety profile over the trial period. Its use can help to reduce the complexity of drug regimen in patients with type 2 diabetes while maintaining a good safety and efficacy profile.

KW - DURATION-1 trial

KW - Exenatide

KW - GLP-1 receptor agonist

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=77955791233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955791233&partnerID=8YFLogxK

U2 - 10.1517/14656566.2010.497142

DO - 10.1517/14656566.2010.497142

M3 - Comment/debate

C2 - 20536293

AN - SCOPUS:77955791233

SN - 1465-6566

VL - 11

SP - 2269

EP - 2271

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 13

ER -

Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this